JAMA's policy does not go far enoughBMJ 2006; 332 doi: http://dx.doi.org/10.1136/bmj.332.7536.305-a (Published 02 February 2006) Cite this as: BMJ 2006;332:305
- Stephen J Senn, professor of statistics ([email protected])
- Department of Statistics, University of Glasgow, Glasgow G12 8QQ
EDITOR—The main objection I have to the JAMA policy is not that it requires independent validation of analysis but that it seems to require it only for studies sponsored by the pharmaceutical industry.1 There have been a whole host of examples, ranging from McBride's “studies” …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial